Hepatic steatosis in chronic hepatitis C: Baseline host and viral characteristics and influence on response to therapy with peginterferon α-2a plus ribavirin

K. R. Reddy, S. Govindarajan, P. Marcellin, D. Bernstein, J. L. Dienstag, H. Bodenheimer, Jorge Rakela, D. Messinger, G. Schmidt, A. Ackrill, S. J. Hadziyannis

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Hepatic steatosis is common in hepatitis C virus (HCV)-infected patients and may be associated with the metabolic syndrome. We studied steatosis in patients treated with peginterferonα-2a plus ribavirin. Forty-five of 207 patients (22%) had >5% hepatic steatosis at baseline. Significantly more patients with steatosis than without were HCV genotype 3 (51%vs 14%; P < 0.0001) had higher HCV-RNA (P = 0.0045), body weight (P = 0.0176), body mass index (BMI, P = 0.0352) and serum triglycerides (TG) (P = 0.0364), hypertriglyceridaemia (P = 0.0009), elevated blood pressure/history of hypertension (P = 0.0229) and lower cholesterol (P = 0.0009). Significant steatosis predictors were genotype 3 (OR 9.04, 95% CI 3.85-21.21, P < 0.0001), HCV-RNA (OR 2.96, 1.49-5.88, P = 0.0019) and triglycerides (OR 1.06, 1.02-1.11, P = 0.0071). In genotype 3 patients, HCV-RNA was the only significant predictor (OR 11.15, 2.60-47.81, P = 0.0012). In non-genotype 3 patients, hypertriglyceridaemia was the only significant predictor (OR 1.07, 1.02-1.12, P = 0.0041). 134 of 207 patients (65%) achieved an sustained virological response (SVR) with peginterferon α-2a plus ribavirin, similar to the overall response rate. In genotype 3 patients with an SVR, steatosis decreased from 48% to 13% (baseline to end-point). No change was seen in the steatosis rate in non-genotype 3 patients with an SVR. This large and comprehensive analysis of a large data base from a multinational trial further adds to the observations that chronic HCV is associated with hepatic steatosis in approximately a fifth of patients. Further, features of the metabolic syndrome are associated with hepatic steatosis in most of these patients. Steatosis is significantly more common in genotype 3 compared with other genotypes, and in these patients, an SVR is associated with steatosis clearance.

Original languageEnglish (US)
Pages (from-to)129-136
Number of pages8
JournalJournal of Viral Hepatitis
Volume15
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Ribavirin
Chronic Hepatitis C
Liver
Hepacivirus
Genotype
Therapeutics
Hypertriglyceridemia
RNA
Triglycerides
Body Mass Index
Cholesterol
Body Weight
Databases

Keywords

  • Baseline predictors
  • Chronic hepatitis C virus
  • HCV genotype
  • Metabolic syndrome
  • Peginterferon α-2a
  • Steatosis
  • Sustained virological response

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Hepatic steatosis in chronic hepatitis C : Baseline host and viral characteristics and influence on response to therapy with peginterferon α-2a plus ribavirin. / Reddy, K. R.; Govindarajan, S.; Marcellin, P.; Bernstein, D.; Dienstag, J. L.; Bodenheimer, H.; Rakela, Jorge; Messinger, D.; Schmidt, G.; Ackrill, A.; Hadziyannis, S. J.

In: Journal of Viral Hepatitis, Vol. 15, No. 2, 02.2008, p. 129-136.

Research output: Contribution to journalArticle

Reddy, KR, Govindarajan, S, Marcellin, P, Bernstein, D, Dienstag, JL, Bodenheimer, H, Rakela, J, Messinger, D, Schmidt, G, Ackrill, A & Hadziyannis, SJ 2008, 'Hepatic steatosis in chronic hepatitis C: Baseline host and viral characteristics and influence on response to therapy with peginterferon α-2a plus ribavirin', Journal of Viral Hepatitis, vol. 15, no. 2, pp. 129-136. https://doi.org/10.1111/j.1365-2893.2007.00901.x
Reddy, K. R. ; Govindarajan, S. ; Marcellin, P. ; Bernstein, D. ; Dienstag, J. L. ; Bodenheimer, H. ; Rakela, Jorge ; Messinger, D. ; Schmidt, G. ; Ackrill, A. ; Hadziyannis, S. J. / Hepatic steatosis in chronic hepatitis C : Baseline host and viral characteristics and influence on response to therapy with peginterferon α-2a plus ribavirin. In: Journal of Viral Hepatitis. 2008 ; Vol. 15, No. 2. pp. 129-136.
@article{4346b3799ba34b53a5a6025b790cc440,
title = "Hepatic steatosis in chronic hepatitis C: Baseline host and viral characteristics and influence on response to therapy with peginterferon α-2a plus ribavirin",
abstract = "Hepatic steatosis is common in hepatitis C virus (HCV)-infected patients and may be associated with the metabolic syndrome. We studied steatosis in patients treated with peginterferonα-2a plus ribavirin. Forty-five of 207 patients (22{\%}) had >5{\%} hepatic steatosis at baseline. Significantly more patients with steatosis than without were HCV genotype 3 (51{\%}vs 14{\%}; P < 0.0001) had higher HCV-RNA (P = 0.0045), body weight (P = 0.0176), body mass index (BMI, P = 0.0352) and serum triglycerides (TG) (P = 0.0364), hypertriglyceridaemia (P = 0.0009), elevated blood pressure/history of hypertension (P = 0.0229) and lower cholesterol (P = 0.0009). Significant steatosis predictors were genotype 3 (OR 9.04, 95{\%} CI 3.85-21.21, P < 0.0001), HCV-RNA (OR 2.96, 1.49-5.88, P = 0.0019) and triglycerides (OR 1.06, 1.02-1.11, P = 0.0071). In genotype 3 patients, HCV-RNA was the only significant predictor (OR 11.15, 2.60-47.81, P = 0.0012). In non-genotype 3 patients, hypertriglyceridaemia was the only significant predictor (OR 1.07, 1.02-1.12, P = 0.0041). 134 of 207 patients (65{\%}) achieved an sustained virological response (SVR) with peginterferon α-2a plus ribavirin, similar to the overall response rate. In genotype 3 patients with an SVR, steatosis decreased from 48{\%} to 13{\%} (baseline to end-point). No change was seen in the steatosis rate in non-genotype 3 patients with an SVR. This large and comprehensive analysis of a large data base from a multinational trial further adds to the observations that chronic HCV is associated with hepatic steatosis in approximately a fifth of patients. Further, features of the metabolic syndrome are associated with hepatic steatosis in most of these patients. Steatosis is significantly more common in genotype 3 compared with other genotypes, and in these patients, an SVR is associated with steatosis clearance.",
keywords = "Baseline predictors, Chronic hepatitis C virus, HCV genotype, Metabolic syndrome, Peginterferon α-2a, Steatosis, Sustained virological response",
author = "Reddy, {K. R.} and S. Govindarajan and P. Marcellin and D. Bernstein and Dienstag, {J. L.} and H. Bodenheimer and Jorge Rakela and D. Messinger and G. Schmidt and A. Ackrill and Hadziyannis, {S. J.}",
year = "2008",
month = "2",
doi = "10.1111/j.1365-2893.2007.00901.x",
language = "English (US)",
volume = "15",
pages = "129--136",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Hepatic steatosis in chronic hepatitis C

T2 - Baseline host and viral characteristics and influence on response to therapy with peginterferon α-2a plus ribavirin

AU - Reddy, K. R.

AU - Govindarajan, S.

AU - Marcellin, P.

AU - Bernstein, D.

AU - Dienstag, J. L.

AU - Bodenheimer, H.

AU - Rakela, Jorge

AU - Messinger, D.

AU - Schmidt, G.

AU - Ackrill, A.

AU - Hadziyannis, S. J.

PY - 2008/2

Y1 - 2008/2

N2 - Hepatic steatosis is common in hepatitis C virus (HCV)-infected patients and may be associated with the metabolic syndrome. We studied steatosis in patients treated with peginterferonα-2a plus ribavirin. Forty-five of 207 patients (22%) had >5% hepatic steatosis at baseline. Significantly more patients with steatosis than without were HCV genotype 3 (51%vs 14%; P < 0.0001) had higher HCV-RNA (P = 0.0045), body weight (P = 0.0176), body mass index (BMI, P = 0.0352) and serum triglycerides (TG) (P = 0.0364), hypertriglyceridaemia (P = 0.0009), elevated blood pressure/history of hypertension (P = 0.0229) and lower cholesterol (P = 0.0009). Significant steatosis predictors were genotype 3 (OR 9.04, 95% CI 3.85-21.21, P < 0.0001), HCV-RNA (OR 2.96, 1.49-5.88, P = 0.0019) and triglycerides (OR 1.06, 1.02-1.11, P = 0.0071). In genotype 3 patients, HCV-RNA was the only significant predictor (OR 11.15, 2.60-47.81, P = 0.0012). In non-genotype 3 patients, hypertriglyceridaemia was the only significant predictor (OR 1.07, 1.02-1.12, P = 0.0041). 134 of 207 patients (65%) achieved an sustained virological response (SVR) with peginterferon α-2a plus ribavirin, similar to the overall response rate. In genotype 3 patients with an SVR, steatosis decreased from 48% to 13% (baseline to end-point). No change was seen in the steatosis rate in non-genotype 3 patients with an SVR. This large and comprehensive analysis of a large data base from a multinational trial further adds to the observations that chronic HCV is associated with hepatic steatosis in approximately a fifth of patients. Further, features of the metabolic syndrome are associated with hepatic steatosis in most of these patients. Steatosis is significantly more common in genotype 3 compared with other genotypes, and in these patients, an SVR is associated with steatosis clearance.

AB - Hepatic steatosis is common in hepatitis C virus (HCV)-infected patients and may be associated with the metabolic syndrome. We studied steatosis in patients treated with peginterferonα-2a plus ribavirin. Forty-five of 207 patients (22%) had >5% hepatic steatosis at baseline. Significantly more patients with steatosis than without were HCV genotype 3 (51%vs 14%; P < 0.0001) had higher HCV-RNA (P = 0.0045), body weight (P = 0.0176), body mass index (BMI, P = 0.0352) and serum triglycerides (TG) (P = 0.0364), hypertriglyceridaemia (P = 0.0009), elevated blood pressure/history of hypertension (P = 0.0229) and lower cholesterol (P = 0.0009). Significant steatosis predictors were genotype 3 (OR 9.04, 95% CI 3.85-21.21, P < 0.0001), HCV-RNA (OR 2.96, 1.49-5.88, P = 0.0019) and triglycerides (OR 1.06, 1.02-1.11, P = 0.0071). In genotype 3 patients, HCV-RNA was the only significant predictor (OR 11.15, 2.60-47.81, P = 0.0012). In non-genotype 3 patients, hypertriglyceridaemia was the only significant predictor (OR 1.07, 1.02-1.12, P = 0.0041). 134 of 207 patients (65%) achieved an sustained virological response (SVR) with peginterferon α-2a plus ribavirin, similar to the overall response rate. In genotype 3 patients with an SVR, steatosis decreased from 48% to 13% (baseline to end-point). No change was seen in the steatosis rate in non-genotype 3 patients with an SVR. This large and comprehensive analysis of a large data base from a multinational trial further adds to the observations that chronic HCV is associated with hepatic steatosis in approximately a fifth of patients. Further, features of the metabolic syndrome are associated with hepatic steatosis in most of these patients. Steatosis is significantly more common in genotype 3 compared with other genotypes, and in these patients, an SVR is associated with steatosis clearance.

KW - Baseline predictors

KW - Chronic hepatitis C virus

KW - HCV genotype

KW - Metabolic syndrome

KW - Peginterferon α-2a

KW - Steatosis

KW - Sustained virological response

UR - http://www.scopus.com/inward/record.url?scp=37649012154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37649012154&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2893.2007.00901.x

DO - 10.1111/j.1365-2893.2007.00901.x

M3 - Article

C2 - 18184196

AN - SCOPUS:37649012154

VL - 15

SP - 129

EP - 136

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 2

ER -